Cagrilintide-RUO 5mg

PRODUCT SPECIFICATIONS

Attribute	Value
Also Known As	AM833 / NN9838 / Long-Acting Amylin Analog
CAS Number	1415456-99-3
Molecular Formula	C194H312N54O59S2
Molecular Weight	4,409.01 Da
Sequence Length	37 amino acids
Vial Size (nominal)	5mg
Form	White lyophilized powder
Purity (this batch)	99.87% — Freedom Diagnostics COA: 2603130112
Net Peptide Content	6.66mg confirmed
Testing Method	HPLC with UV Detection + Mass Spectrometry
Lot Number	CGL5-1142026
Identity Confirmed	Cagrilintide — Mass Spectrometry confirmed
Receptor Targets	AMY1R, AMY2R, AMY3R, CTR (non-selective agonist)
Half-life	Approximately 159 to 195 hours (6.5 to 8 days) in research models
Working Stock	5mg/mL at 1mL BAC water (approximately 1.33mL usable from 6.66mg net content)
Long-term Storage	-20°C, sealed, up to 24 months
Post-reconstitution	4°C, use within 28 days, do not refreeze
Reconstitution Solvent	Bacteriostatic water
Intended Use	In vitro laboratory research only
SKU	PP-628 (5mg single vial). 10-pack variant SKU: PP-629

Certificate of Analysis

Freedom Diagnostics is a US-owned independent laboratory. They test every batch without input from Profound Peptides on the outcome. The results below come from the actual report for this lot. Verify them yourself at FreedomDiagnosticsTesting.com before you order.

Field	Value
Purity	99.871%
Testing Method	LC/MS-MS (HPLC with UV Detection + Mass Spectrometry)
Identity	Cagrilintide — confirmed
Net Peptide Content	6.66mg
Lot Number	CGL5-1142026
COA Accession	2603130112
Search Code	Prof2603130112
Testing Lab	Freedom Diagnostics (USA)
Principal Chemist	Alex Johnson
Received	03/13/2026
Reported	03/15/2026

Download COA PDF

How Cagrilintide Works

Cagrilintide is built from the human amylin sequence and engineered to solve amylin’s biggest research liability: native amylin aggregates into amyloid fibrils in solution, which makes it unstable and hard to work with experimentally. Cagrilintide keeps amylin’s receptor-binding activity while removing that instability.

Receptor Engagement

Cagrilintide is a non-selective agonist across the amylin receptor subtypes AMY1R, AMY2R, and AMY3R, and it also activates the calcitonin receptor (CTR). That four-receptor binding profile is sometimes described in the literature as a dual amylin and calcitonin receptor agonist, or DACRA. This is a distinct signaling family from GLP-1R, GIPR, or GCGR, so cagrilintide does not overlap mechanistically with incretin peptides like Semaglutide or Tirzepatide. It reaches these receptors through the area postrema and dorsal vagal complex in the brainstem, regions with dense amylin receptor expression and no blood-brain barrier, which is where amylin signaling drives satiety and reduced food intake in research models.

Structural Features That Solve Fibrillation and Extend Half-life

Native human amylin carries two structural problems for lab use: it fibrillates in solution, and it clears the body in minutes. Cagrilintide’s design addresses both. Substitutions at positions 25, 28, and 29, adapted from the naturally non-amyloidogenic rat amylin sequence, reduce the peptide’s tendency to form beta-sheet structures and aggregate. A second pair of substitutions at positions 14 and 17 introduces a stabilizing salt bridge that locks the central alpha-helix in place. A C-terminal proline improves potency at the calcitonin receptor specifically. For half-life, an N-terminal C20 fatty diacid, attached through a gamma-glutamate linker, binds reversibly to albumin in circulation. That albumin binding is what stretches cagrilintide’s half-life out to roughly 159 to 195 hours in research models, a range established by Enebo et al. (Lancet, 2021), supporting once-weekly dosing intervals instead of the minutes-long clearance of native amylin.

Key Structural and Binding Features for Assay Design

Feature	Detail
Receptor targets	AMY1R, AMY2R, AMY3R, CTR (non-selective)
Receptor count	4, no GLP-1R, GIPR, or GCGR activity
Fibrillation resistance	Positions 25, 28, 29 substituted from rat amylin sequence
Helix stabilization	14E/17R salt bridge substitution
CTR potency	Enhanced via C-terminal proline
Albumin binding	Reversible, C20 fatty diacid via gamma-Glu linker at the N-terminus
Half-life (research models)	Approximately 159 to 195 hours (6.5 to 8 days)
Disulfide bridge	Cys3 to Cys8, preserved from native amylin

Research Applications

Each bullet states what researchers actually study with this compound and why.

• Amylin and calcitonin receptor pharmacology. Fletcher et al. (J Pharmacol Exp Ther, 2021) characterized cagrilintide’s binding and functional activity across the amylin and calcitonin receptor family and confirmed its non-selective agonist profile. Labs studying this receptor family specifically, rather than the GLP-1 pathway, use Cagrilintide as the reference compound.
• Obesity and body weight regulation models. Lau et al. (Lancet, 2021) ran a dose-finding monotherapy trial across 706 adults and established a clear dose-dependent weight loss and waist circumference response. Rodent diet-induced obesity models use the same dosing logic to study amylin-driven weight regulation independent of incretin signaling.
• Dual-hormone and combination protocol research. Enebo et al. (Lancet, 2021) established the safety and pharmacokinetic profile of Cagrilintide combined with semaglutide 2.4mg in a Phase 1b trial. Studies that model how amylin and GLP-1 signaling interact when co-administered, rather than in isolation, build on this combination framework.
• Appetite and satiety signaling. Amylin receptors sit densely in the area postrema and nucleus tractus solitarius, brainstem regions that process satiety signals independently of the hypothalamic pathways GLP-1 primarily engages. Protocols measuring food intake, meal termination, or central satiety response use Cagrilintide to isolate this signaling arm.
• Fibrillation-resistant peptide engineering reference. Native amylin’s tendency to form amyloid fibrils makes it a difficult peptide to formulate and study directly. Kruse et al. (J Med Chem, 2021) documented the specific substitution and lipidation strategy that solved this, which makes Cagrilintide a useful case study for labs working on aggregation-resistant peptide design more broadly.
• Glycemic control in combination with incretin agonists. Davies et al. (NEJM, 2025) tested the Cagrilintide and semaglutide combination in a type 2 diabetes population and measured glycemic and weight outcomes against each monotherapy. Labs modeling glucose control alongside weight regulation reference this trial design.

How Cagrilintide Compares to Semaglutide for Research

This table targets the comparison queries researchers use when choosing between compounds. Both products are available from ProfoundPeptides.

	Cagrilintide RUO 5mg	Semaglutide RUO 10mg
Backbone	Amylin analog	GLP-1 analog
Receptor targets	AMY1R, AMY2R, AMY3R, CTR	GLP-1R only
Receptor count	4	1
Lipidation	C20 fatty diacid, N-terminal, gamma-Glu linker	C18 fatty diacid, position 26, gamma-Glu/OEG linker
Half-life	Approximately 159 to 195 hrs	Approximately 168 hrs
Phase of evidence	Phase 2 monotherapy complete, Phase 3 combination trials complete	Phase 3 complete
Choose this when	Studying amylin or calcitonin receptor mechanisms, central satiety signaling outside the incretin pathway, or dual-hormone combination protocols	Isolating GLP-1R mechanisms; need a clean single-receptor reference compound

Storage and Reconstitution

Before You Open the Vial

Pull the vial from -20°C and let it sit at room temperature for 10 to 15 minutes before opening. A cold vial draws condensation when it meets ambient air, and that moisture can reach the lyophilized powder through the stopper before you add your solvent. This one extra step removes a variable before the experiment begins.

Reconstitution Steps

Add 1mL of bacteriostatic water slowly down the inside wall of the vial, not directly onto the powder. Tilt the vial so the stream contacts the glass first. Swirl gently for 30 to 60 seconds until the powder fully dissolves. Do not vortex or shake. The solution is clear when ready. Persistent cloudiness after 90 seconds of gentle swirling means you should request a replacement vial. At 1mL you get a 5mg/mL nominal working stock and approximately 1.33mL of usable solution from the 6.66mg confirmed net content.

Managing the Vial Across a Protocol

This 5mg vial is sized for a focused single-arm use. If your protocol does not use the full working volume in one session, aliquot immediately after reconstitution into single-use volumes and store at 4°C. Use within 28 days. Do not refreeze. If your study needs more than 5mg total, calculate your compound requirement before ordering. The 10-pack option covers larger or multi-arm protocols while keeping every vial on record with its own COA.

Condition	Guidance
Lyophilized, sealed	-20°C, up to 24 months
Post-reconstitution	4°C, use within 28 days, do not refreeze
Temperature excursion	Above 8°C post-reconstitution, treat as compromised
Condensation risk	Warm vial 10 to 15 minutes before opening
Solvent	Bacteriostatic water (sterile saline if BAC water is unavailable)

Freedom Diagnostics confirmed 6.66mg net peptide content for this lot (COA: 2603130112). The lyophilized material appears as a thin compressed cake at the vial bottom. This is normal at this purity level and does not mean the vial is underfilled.

Published Research

Five studies covering the core Cagrilintide literature. Each entry states what the study actually found, not just that it exists.

Study	Publication	What it found
Kruse T et al. (2021) Peptide development and chemistry	J Med Chem 64(15):11183 PMID: 34288673	Documented the substitution and lipidation strategy that converted amyloid-prone human amylin into a stable, fibrillation-resistant, long-acting analog. The foundational chemistry paper behind cagrilintide’s design.
Fletcher MM et al. (2021) Receptor pharmacology	J Pharmacol Exp Ther 377(3):417 PMID: 33727283	Characterized cagrilintide’s activity across the amylin and calcitonin receptor family and confirmed its non-selective agonist profile at AMY1R, AMY2R, AMY3R, and CTR.
Lau DCW et al. (2021) Phase 2 monotherapy dose-finding	Lancet 398(10317):2160 PMID: 34798060	Established a dose-dependent weight loss and waist circumference response across 706 adults over 26 weeks and defined the dosing range used in later trials.
Enebo LB et al. (2021) Phase 1b combination trial	Lancet 397(10286):1736 PMID: 33894838	Established safety, tolerability, and pharmacokinetics of Cagrilintide combined with semaglutide 2.4mg, the trial that opened the combination program.
Garvey WT et al. (2025) REDEFINE-1, Phase 3	NEJM 393(7):635 PMID: 40544433	Measured weight loss with the Cagrilintide and semaglutide combination against each monotherapy and placebo at 68 weeks in adults with obesity, with the combination outperforming either compound alone.

This product is for in vitro laboratory and scientific research use only. Not FDA approved. Not for human consumption, veterinary use, or diagnostic purposes.